A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in ...

The ASPIRE trial showed SURE's noninferiority to URS in stone-free rate for nephrolithiasis treatment. SURE demonstrated superior stone clearance and residual stone volume outcomes, unaffected by ...

The therapeutic response rate was 79% at 24 months, which is comparable to the rates seen at 6 months (78%) and 12 months (82%).

“I think there's a lot to be done and combination therapies, other drugs that can be instilled into this device. It's a bright future,” says Siamak Daneshmand, MD. In this video, Siamak Daneshmand, MD ...

The series empowers surgeons to make informed family planning decisions through education, resources, and peer networking. Research indicates female surgeons face higher pregnancy complications and ...

New research better defines the link between cardiovascular disease risk and prevalence of ED per serum ceramide levels.

“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.

Vibegron is the first beta-3 agonist approved for OAB symptoms in men treated for BPH, showing significant symptom improvement. The phase 3 COURAGE trial demonstrated significant reductions in ...

"We found that with a 5-year Kaplan-Meier survival analysis that patients with varicocele had worse outcomes than patients without varicocele," says Muhammed A. Moukhtar Hammad, MBBCh. In this video, ...

home / case-based-peer-perspectives / optimizing-sequential-therapy-in-metastatic-castration-resistant-prostate-cancer-mcrpc-with-bone ...